TFF Pharma Q1 net loss $5.7M, cash $3.2M; raised $6M in public offerings since March

TFF Pharmaceuticals, Inc.

2024-Q1 EPS reported -$2.40 revenue$203,273

Net loss of $5.7M improved from $7.1M in Q1 2023; R&D spend $3.6M, G&A $2.4M.
Cash and equivalents $3.2M at March 31; completed $4.8M offering May 1, plus $1.2M in March.
Phase 2 TFF TAC: 8/8 patients transitioned from oral; 4/4 completed 12 weeks and entered extension.
TFF VORI: 5/6 patients achieved clinical and mycologic response; no IPA-related mortality.
Company prioritizing TFF TAC; exploring strategic alternatives for TFF VORI; FDA feedback expected in Q2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TFF Pharmaceuticals, Inc. reported fiscal quarter ended March 31, 2024 results: net income Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7.

Period: fiscal quarter ended March 31, 2024
Net income: Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7
Result: reported results

Exact text from the filing

Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7.1 million for the year ended March 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001213900-24-042919

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.